Evidence map›Paper›PMID 36201089›Full record

Trial reportInternational journal of clinical oncology2022

Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study).

Hiroshi Matsuoka, Takeshi Yamada, Ryo Ohta, Yoichiro Yoshida, Tatsuyuki Watanabe, Makoto Takahashi, Chihiro Kosugi, Atsuko Fukazawa, Hidekazu Kuramochi, Akihisa Matsuda and 8 more

Abstract readMulticenter StudyClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 1 country.

Hiroshi Matsuoka *Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Takeshi Yamada *Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan. y-tak@nms.ac.jp.ORCID http://orcid.org/0000-0002-1436-7482
Ryo OhtaDepartment of Surgery, Fujita Health University, Nagoya, Aichi, Japan.
Yoichiro YoshidaDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Tatsuyuki WatanabeThird Department of Internal Medicine, University of Occupational and Environmental Health, Fukuoka, Japan.
Makoto TakahashiDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Chihiro KosugiDepartment of Surgery, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan.
Atsuko FukazawaDepartment of Gastroenterological Surgery, Iwata City Hospital, Shizuoka, Japan.
Hidekazu KuramochiDepartment of Chemotherapy, Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo, Chiba, Japan.
Akihisa MatsudaDepartment of Surgery, Fujita Health University, Nagoya, Aichi, Japan.
Hiromichi SonodaDepartment of Surgery, Fujita Health University, Nagoya, Aichi, Japan.
Hiroshi YoshidaDepartment of Surgery, Fujita Health University, Nagoya, Aichi, Japan.
Suguru HasegawaDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Kazuhiro SakamotoDepartment of Coloproctological Surgery, Juntendo University Faculty of Medicine, Tokyo, Japan.
Toshiaki OtsukaDeparment of Hygiene and Public Health, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Keiji HirataFirst Department of Surgery, University of Occupational and Environmental Health, Fukuoka, Japan.
Keiji KodaDepartment of Surgery, Teikyo University Chiba Medical Center, Ichihara, Chiba, Japan.
TAS CC4 Study Group
Fujita Health University · JPFukuoka University · JPJuntendo University · JPNippon Medical School · JPTeikyo University Chiba Medical Center · JPUniversity of Occupational and Environmental Health Japan · JPIwata City Hospital · JPTokyo Women's Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTAS-102 improves overall survival (OS) of patients with refractory colorectal cancer (CRC), resulting in median progression-free survival (PFS) of 2.0 months (RECOURSE trial). Subsequently, a combination of TAS-102 and bevacizumab was shown to extend median PFS by 3.7 months. However, approximately half of these patients experience grade 3/4 neutropenia. In this study, we evaluated whether biweekly TAS-102 and bevacizumab therapy has efficacy equal to that of conventional TAS-102 and bevacizumab therapy and whether it reduces adverse hematological effects.

methodsThis phase II, investigator-initiated, open-label, single-arm, multicenter study was conducted in Japan. Eligible patients had previously received first- and second-line chemotherapy for metastatic CRC. TAS-102 (35 mg/m

results44 patients with metastatic colorectal cancer were enrolled in this study. Median PFS was 4.6 months (95% confidence interval [95% CI] 3.6-5.3) and median OS was 10.5 months (95% CI 9.6-11.4). A partial response was observed in 2 patients (4.5%, 95% CI 0.4-16.0%). The most common adverse event above grade 3 was neutropenia (7 patients, 15.9%, 95% CI 7.6-29.7%).

conclusionsBiweekly TAS-102 and bevacizumab therapy as third-line chemotherapy appears as effective as conventional TAS-102 and bevacizumab therapy, and this approach reduces adverse hematological effects.

Indexed as

Colorectal NeoplasmsNeutropeniaAntineoplastic Combined Chemotherapy ProtocolsBevacizumabDrug CombinationsFluorouracilHumansNeoplasm Recurrence, LocalPyrrolidinesThymineTrifluridineBevacizumabDrug CombinationsFluorouracilPyrrolidinesThymineTrifluridinetrifluridine tipiracil drug combinationBevacizumabChemotherapyColorectal cancerNeutropeniaTAS-102

Identifiers

PMID36201089
OpenAlexW4302291056

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.